THX Pharma Announces Cash Position as of December 31, 2025
THX Pharma, a biopharmaceutical company specializing in rare neurological diseases, has disclosed its cash position as of December 31, 2025. This announcement comes in the context of a strategic partnership with Biocodex announced in February 2026.
Financial Overview as of Year-end 2025
As of December 31, 2025, THX Pharma had a cash reserve of €7.764 million. In line with the agreement reached with Biocodex on February 10, 2026, the company will receive an initial payment of €12 million in March 2026. This contribution, added to the available cash at the end of December 2025 and an advance on funding for the Batten-1 program, results in a pro forma cash position of €21.7 million. In 2025, THX Pharma raised nearly €8 million.
Focus on Key Development Programs
The company remains focused on two main programs. TX01, a new formulation aimed at treating Gaucher's disease and Niemann-Pick type C, is expected to have its regulatory filings in 2026, with commercialization planned as early as 2027 by Biocodex and Exeltis in their respective territories. Batten-1, a drug candidate targeting the juvenile form of Batten disease, benefits from a global licensing agreement with Biocodex, which will cover all development costs aiming for commercialization by the end of 2029.
